A Half-Century of Inspiration: An Interview with Hamilton Smith by Gitschier, Jane
Interview
A Half-Century of Inspiration: An Interview with
Hamilton Smith
Jane Gitschier*
Department of Medicine and Pediatrics, University of California San Francisco, San Francisco, California, United States of America
In 1962, Hamilton Smith abandoned a
career in medicine to follow his passion for
the emerging field of molecular biology;
within six years, he had made the discovery
of a lifetime. As a new Johns Hopkins
faculty member, Smith, together with his
first graduate student, Kent Wilcox, geared
up to study recombination in vitro but
instead discovered the restriction enzyme
‘‘R’’ in Haemophilus influenzae. By cobbling
together crude techniques, Smith, along
with Wilcox and later Tom Kelly, showed
that R cleaves DNA at a specific recogni-
tion sequence, a palindromic site, yielding
blunt-ended DNA fragments. Now known
as HindII, R proved to be the first of an
enormous class of Type II restriction
enzymes, and as such, presaged gene
cloning, allowed DNA to be reproducibly
fragmented and then sequenced, and
enabled physical mapping of genomes.
Smith went on to discover DNAmethylases
that constitutetheotherhalfof the bacterial
host restriction and modification systems,
as hypothesized by Werner Arber of
Switzerland. Together with Arber and his
Hopkins colleague Daniel Nathans, who
first used the enzyme on SV40 DNA and
demonstrated discrete bands on a tube gel,
Smith shared the Nobel Prize for Physiol-
ogy or Medicine in 1978.
Smith’s curiosity and his gift for hands-
on research continued to guide him
through a highly productive career at
Hopkins for more than three decades,
when a chance meeting with Craig
Venter, who had just launched The
Institute for Genome Research (TIGR),
turned his attention to sequencing the
Haemophilus genome. In 1998, he gave up
his faculty position at Hopkins and has
been working with Venter ever since.
Currently, Smith (Image 1) spearheads
the highly visible synthetic biology pro-
gram at the J. Craig Venter Institute
(JCVI) in San Diego. And that is where I
caught up with him in late October.
I discovered a soft-spoken and cheerful
man whose focus and energy have buoyed
him through a half-century of science and
who shows no signs of wearing down. We
pick up the conversation where Ham gets
the idea of going into research.
Gitschier: Let’s start with how you got
involved in basic research after going to
medical school.
Smith: After my internship [at Barnes
Hospital in Saint Louis], the plan was just
to go on with the system—residency. At
that time there was no draft, but there was
a doctors’ draft. There weren’t enough
doctors volunteering to serve, so by lottery
they would select one out of every ten
physicians for a two-year period. And my
number came up. I was just married, so we
headed off to San Diego for two years in
the Navy.
I was head of the dispensary at the 11th
Naval District Headquarters, down on
Pacific Highway. I had about seven or
eight corpsmen assisting me. I was the
doctor taking care of about 1,100 civilians
and 500–600 military, mostly admirals,
captains, commanders, and lieutenants
because it was a headquarters and a
supply depot area.
Gitschier: That must have been a
great experience, in terms of being a
clinician.
Smith: That was real medicine! I mean
I did physical examinations. If people got
sick they came in to see me, and I would
treat them. It was a very good two years.
The plan up to that point was to continue
on in medicine and become a practicing
physician. But maybe an academic posi-
tion, because I had the idea of wanting to
do some research.
Gitschier: How did that idea of doing
research get started?
Smith: From birth, I guess. [Laughter]
I’ve always had kind of an inquiring mind.
I always wanted to know how things
worked.
I was first introduced to molecular
biology while I was here in the Navy. And
that laid the seeds for my eventually getting
out of medicine and going into research.
Gitschier: How was that?
Smith: I had one afternoon a week free.
AndIcould gouptotheNavalHospital.So
I went up to the endocrine clinic, and
worked there on, I think, Wednesday
afternoons. And saw people with various
disorders, among them, some genetic-type
defects. And I started reading up on that.
Somebody found that if you put the cells on
a slide and then mashed the coverslip with
your thumb, the cells would spread out and
you could count the chromosomes. It was
called a ‘‘squash prep,’’ and if you stained
with orcein, you could very clearly see and
count the chromosomes.
I read an article saying that there were
46 chromosomes, and then they started
describing abnormalities in the chromo-
somes, like Turner syndrome, which is
XO, and Klinefelter, which is XXY. And
those people were coming into the endo-
crine clinic, so I started reading up on that,
and I turned to basic genetics texts. And
there it was—Watson and Crick. 1957 was
when I found out about it, in a general
college text by Dobzhansky. And there
was a just a little bit on it.
So, I got very interested because I
could see the implications of it. And there
were no textbooks on molecular biology. I
don’t know if the term was even invented
at that point. But there were two
paperback compilations of papers. One
was Bacterial Genetics by Adelberg and the
other was Stent’s book on bacterial
viruses. So if you read those, you were
on the cutting edge!
It was when I started my medical
residency at Ford Hospital in Detroit that
I would go to the library after eating lunch
and sit in an easy chair. I was reading
Mark Adams’s book Bacteriophages that
came out at that time and The Chemical
Basis of Heredity, which came out in 1957. I
was really very interested in this now, but I
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leave medicine at that point.
Gitschier: Because you still have a
number of years of residency to go!
Smith: Right. So here I am in the
second year of my residency and I had a
very good friend, Pierre Caron, he was a
French guy from Montreal. And he was
kind of interested in science as well. And
we had read about the Barr bodies, by
which you could very easily determine
male or female. So, we decided we’d play
with that.
I can still remember we were making a
stock solution of orcein. It was in the hood;
we were heating up the acetic acid in a
flask. And he says, ‘‘OK, I’m going to add
the orcein,’’ and he reached in and put it
in, and it went ‘‘Poof!’’ ‘cause we didn’t
have boiling chips, and we had super-
heated the solution, and the whole hood
was covered with purple stain.
Anyway, we got our stock solution and
we started getting some buccal smears and
started looking at Barr bodies. We were
rotating through endocrinology at that
point and there were some people with a
question of whether they had a chromo-
somal defect or not. And the doctors in the
clinic didn’t know about this stuff, so we
kind of introduced it.
Then I ran into Caron later on in the
second year, and he said that he had
applied for an NIH [National Institutes of
Health] fellowship and he was going to
take a two-year research fellowship before
practicing. And so I thought, ‘‘Gee, that
sounds good!’’ Sputnik went up in ’57, so
money was flooding into the system.
So I called my father and told him what
I was planning to do. And he said, ‘‘Well
there is this fellow Jim Neel at Ann Arbor
[at the University of Michigan],’’ which is
about 40 miles away. ‘‘Why don’t you
drive over and talk to him?’’
Gitschier: How did he know Jim
Neel?
Smith: Interesting story. My father
[who was a professor in education at the
University of Illinois] was up giving a
lecture; and in the cafeteria line, Jim Neel
was just ahead of him. And they struck up
a conversation. Jim Neel had started that
Department [of Human Genetics].
And so, I drove over and talked with
him. He was very interested in me right
away because of my mathematical back-
ground. He was doing statistical and
genetic studies on isolated populations in
the Amazon.
I immediately insulted him, because he
said, ‘‘Would you be interested in doing
this?’’ And I said, ‘‘No, I want to do basic
research.’’ And he said, ‘‘Well, that’s what
I think I’m doing!’’ [Laughter]
Gitschier: But you meant something
closer to the DNA.
Smith: I meant with the DNA and
genes and so on. So when he heard what I
was interested in—phage genetics and
bacterial genetics—he said he had just
hired Mike Levine, and maybe I could
work with him.
Mike was at Brookhaven at the time. He
was working on the Salmonella phage P22.
So I wrote a very brief NIH Fellowship
application. If you had reasonable creden-
tials, it was no big deal [to get one].
Gitschier: Were you still thinking, like
your friend Caron, ‘‘Well, after my
fellowship, I’ll then practice medicine’’?
Smith: No, never again. Not once I got
into the lab and saw that I understood and
had a lot of ideas and so on.
So, [after two years] I had a paper in
PNAS [Proceedings of the National Academy of
Sciences] and then one in Science on
temperature-sensitive mutations of the C
genes, and Mike and I were getting along
really well. Mike offered to make me a
doi:10.1371/journal.pgen.1002466.g001
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FFigure 1. Hamilton Smith. Fresearch associate, which is sort of a junior
faculty position. So I was very happy. I
was paid something like $9,000 a year. I
moved over [from Detroit], bought a
house, still not even thinking about the
future. Probably Mike was worried—he
didn’t say anything though. I continued
working for three [more] years. I think it
was about the second year—about 1965—
that he suggested that maybe I should start
looking for a faculty position.
And then I got a call from Hopkins
[saying] that they would like me to come
out and give a talk.
Gitschier: Do you remember who at
Hopkins called you?
Smith: Yeah, Dan Nathans.
Gitschier: Ah! Had you never met
him before?
Smith: No, but the minute I visited
there and gave the seminar, I knew that
was it.
Gitschier: OK, so, this is something
like 1967—and you are off to Hopkins.
Tell me what you are working on once you
got there and how you made this com-
pletely wild discovery.
Smith: Right. I had become very
interested in lysogeny: the mechanism of
how it’s established, how when the phage
genome enters the cell, it has to make a
decision whether it’s going to replicate
itself or integrate into the genome to make
a lysogen.
While still at Michigan I had discovered
the int gene in Salmonella phage. And I
wanted to get into biochemistry. So I
decided I wanted to try to get an in vitro
integration reaction. There was some early
stuff starting to happen with lambda phage
[which is very similar to P22]. There were
a large number of lambda people. Like 50
of them, I think.
Gitschier: P22 was not as popular.
Smith: There were about two or three
labs. I started out with a grant to study the
integration process. I guess it was just after
a few months that I got to Hopkins with my
grant and everything, that I realized that
the lambda people—there were too many
of them! They were moving in on this area.
And I didn’t want to just do some…
Gitschier: A ‘‘me-too’’ experiment.
Smith: Yeah, exactly. So I decided I
would start looking at general recombina-
tion. And I decided maybe if I had a
transformation system, where I could do
experiments in the test tube with DNA
and then test to see if there was recombi-
nation by transforming, to see if markers
were linked, or not linked—it was kind of
a naı ¨ve thing—but …
It turned out at Hopkins there was
Roger Herriott—just across the street at
the School of Hygiene [and Public
Health]. He had been studying Haemoph-
ilus influenza transformation for about a
dozen years.
Gitschier: So that’s how you got into
the Haemophilus!
Smith: Yeah. So I spent a couple days
working with his technician and learning
how to grow and develop competent cells
and do the assays.
Gitschier: And you couldn’t do this in
Salmonella [the P22 host]; they don’t have
natural transformation?
Smith: No, there is no transformation
there. There is no genetically determined
membrane system for taking up DNA.
Whereas with Haemophilus or with pneumo-
coccus, they all have genetically deter-
mined, very efficient uptake systems for
DNA. And that’s controlled by a couple
dozen genes.
Gitschier: So the idea is you’re going
to make a recombinant in a test tube…
Smith: Right. I would take extracts of
Haemophilus, and then treat two different
DNAs carrying genetic markers and see if
I could recombine them in the test tube,
and then transform to show that I had
double mutants.
I started doing some simple biochemis-
try experiments, and I was joined by a
graduate student, Kent Wilcox. Just to get
him going, I suggested that he take some
phage P22 DNA that was labeled with
3H
or
32P and that I had in the refrigerator. I
said, ‘‘Take this DNA and transform it
into Haemophilus’’ to see what happens.
The idea was to let it go in and then to
recover it from the cell to see what had
happened to the DNA when it went in.
And we were also doing experiments
with labeled Haemophilus DNA at the same
time. And the cells would take it up and
you could recover it again. But when he
did it with the P22, nothing was recovered.
And here’s where good fortune comes
in. Matt Meselson and Robert Yuan had
written a paper describing the first Type I
restriction enzyme [Type I enzymes cut at
a random distance from their recognition
sites], and I gave a talk on it in the journal
club, because it was a really fantastic
paper. For the first time I really under-
stood clearly what restriction and modifi-
cation were. It was very clear now that
there was an enzyme—an endonuclease—
that recognized sites and cleaved the
DNA.
Gitschier: And had you given this
journal club just as Wilcox was doing this
experiment?
Smith: I gave this a week before the
initial idea came to us. I gave the seminar,
he did his experiment, and he couldn’t
recover the foreign DNA from the cell.
And he said, ‘‘Could it be restriction?’’
Gitschier: Oh, he said that?
Smith: Yeah, he said that! And I said,
‘‘No!’’ And I was thinking, obviously he
bummed up the experiment in some way!
Gitschier: But the control worked—
he did recover the Haemophilus DNA.
Smith: Yeah, the control worked.
Gitschier: So he didn’t bum up that
part of the experiment.
Smith: [Laughter] Anyway, it turned
out in subsequent years that is was not
restriction. He couldn’t recover it because
it wasn’t taken up.
Gitschier: Are you kidding?
Smith: I’m not kidding. The foreign
DNA was not taken up because it didn’t
have uptake sites on it.
But I went home that night, and
thought about it, and realized that we
had a very simple assay that we would
know in ten minutes what the answer was.
So, we came in the next morning. What
I had realized was that I had been doing
some work with viscometry, using Hae-
mophilus extracts [which were sonicated to
destroy their own DNA], to see if the DNA
was getting broken down when you add
the extract, or maybe it was getting put
together and becoming more viscous. I
was just playing around, basically. And I
had already learned that [with] the
Haemophilus DNA—nothing happened.
You add extract, the viscosity would stay
the same, just flat.
Gitschier: Tell me a little more about
the experiment.
Smith: The chamber where the reac-
tion is taking place has extract and buffer,
magnesium, and so on. And then we
added the Haemophilus DNA to it and mix
it. And as you draw it back and forth in the
capillary tube, the time it takes to go
through the little hole didn’t change. In
other words, the viscosity [was the same].
The molecules were not getting broken or
anything.
I realized that if we had a restriction
enzyme, it’s an endonuclease. It would
begin to break internally, and the viscosity
would drop very rapidly. A single break
and the viscosity would drop. So we set up
two viscometers—one with Haemophilus
DNA and one with the P22 DNA, added
the extract, mixed, and then started taking
[measurements] as fast as we could do it.
By five minutes, the first point on the P22
was way down, whereas the Haemophilus
was the same. We had something in there
recognizing that it was a foreign DNA:
restriction.
Gitschier: OK. Before we continue on
that, why were you so sure that Wilcox’s
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had been wrong?
Smith: Well, I mean, it was just too
much to expect, you know! ‘Cause we
didn’t know that there were widespread
systems at that time. It [restriction] was in
[E.] coli. The original Meselson enzyme
was in coli.
Gitschier: Right, as was the Werner
Arber stuff.
Smith: Yeah, and I thought maybe it
was a special mechanism in those bacteria.
I mean, I wasn’t dogmatic about it.
Obviously, I started thinking about it.
But the crucial thing was that we had a
simple assay to determine if it was
restriction. I thought if it really is a
restriction enzyme, then with the viscom-
etry, we would be able to detect a single
break very quickly! If he hadn’t made the
observation, of course, we probably
wouldn’t have done the work. And also,
if I hadn’t read that paper and presented it
at the journal club…we never would have
thought of it.
Gitschier: Do you remember what
date that was?
Smith: Yeah, I do! It was May 28th of
1968.
Gitschier: Wow!
Now, let’s fast-forward. Sometime in the
mid-’90s, you started to work with Craig
Venter.
Smith: Yeah, sure. Of course the
human genome project started officially
around 1990, but there was already
money appropriated as early as 1987.
And people were applying for grants, and I
got one of those early grants, an R01, just
to size the Haemophilus genome using
restriction fragments.
So, at that point Craig was not in
genomics. It was not till ’91 that he began
to become prominent.
Gitschier: And that was because of the
ESTs [expressed sequence tags]?
Smith: ESTs, yes, and the first paper
was published in ’91. And that aroused a
lot of academic anger, because of the
patent issue. So that’s when I first heard
about Craig; he was in the center of a big
controversy.
It was not until the spring of ’93 that we
both happened to go to a meeting in
Bilbao, Spain. The meeting was convened
to discuss legal, religious, and scientific
issues related to the human genome
project.
I was chairing one of the sessions in the
meeting, actually, and Craig spoke in that.
At the end of the day, I had gone over the
hotel and into the bar just to relax a little
bit, and Craig walks in and orders a drink.
We started talking about how we got into
science and there were some similarities.
He was a very congenial guy. I think
when I first met him, I said something to
the effect of ‘‘Where are your horns,
because in academia you are the devil!’’
[Laughter]
Gitschier: And what did he say?
Smith: He didn’t say anything—he just
sort of grinned. We really hit it off well,
and [later] he asked would I be interested
in being on his scientific advisory council
for his new Institute, which had just
started about six months before that. So,
I said, ‘‘I’ll drive down and take a look.’’
Gitschier: And this is TIGR.
Smith: This is TIGR. He had left NIH
at that point. He had money from Human
Genome Sciences and set up his Institute.
He had an up-and-running lab and he was
doing EST sequencing.
So I went down and took a look and I
was totally blown away. He had this huge
room with 30 sequencers. He was crank-
ing out something like 400,000 base pairs
a day, of raw sequence. That was huge.
So, I joined the council. They had their
first annual meeting at some river retreat
in Maryland, and I went to that. We were
sitting around and he was describing how
they were finishing off the EST sequencing
sometime in early ’94.
And I suddenly, I think a light went on
in my head, and I said, ‘‘Haemophilus!I f
they can do 400,000 a day, we can
sequence it in a few weeks.’’ So I raised
my hand, and I said, ‘‘You call yourself
The Institute of Genomic Research, let’s
do a genome! How about Haemophilus
influenzae?’’
Gitschier: So, at that point, he didn’t
have an idea that he was going to go into
sequencing the human genome?
Smith: No. That was not yet on the
radar screen. Even sequencing a whole
bacterium was barely a blip. And he was
very interested, because they were winding
down the other stuff and he wanted
something else to do. So I said, ‘‘I’ll make
a library of the genome and maybe we can
sequence it.’’
But I was thinking—and everybody at
that time was thinking—that you make a
library, you map the pieces, and then you
sequence each piece. And then put it all
together. That’s the way they were doing
coli, and it took almost ten years.
I went back to my lab group and I said,
‘‘Lookit, we could get the sequence of
Haemophilus. We have to make this library
and make these pieces.’’ And my group—
they’ve all got their own projects. And
they’re looking at me, and they said,
‘‘That’ll take a year and we don’t have a
grant for it.’’ Blah blah. I got very upset. I
stormed off to my office.
Gitschier: Really, were you angry?
Smith: I was really disappointed with
the group—here’s an opportunity of a
lifetime, and they didn’t want to jump on
it. I walked into my office and started
thinking about it.
And I kept thinking. And I thought that
we don’t have the money and the time to
do all this mapping—we’ve got to do it
another way. And Craig is doing random
shot-gun of ESTs and then assembling
them into full transcripts. Let’s do it that
way. Let’s make a single library, sequence
a few tens of thousands of fragments, and
put them all together with a computer.
And so, I drove down and everybody
got together. It was a group of about 40–
50 people—technicians and everyone—it
was a nice group in those days. So, I got
up to the board and I showed a couple of
slides of a table, showing how as you
sequence 5,000 fragments, you had this
amount of genome completed, 10,000 you
had this…and so on. And said, if we do
40,000, we’ll close all the gaps.
And Craig, of course, was very excited.
Everybody I think realized this was the
way to do it. But Craig says, ‘‘No, we don’t
want to sequence 40,000. We’ll sequence
about 25,000, because you may never be
able to close the gap. What we’ll do is to
assemble the 25,000 and we’ll close the
gaps after that.’’ And that’s the way we did
it.
Gitschier: Now, at some point you just
leave Johns Hopkins altogether and go to
work—was it at TIGR?
Smith: Yeah, 1998, July 1.
Gitschier: So you had been at Hop-
kins 31 years. What prompted you to close
your lab at Hopkins and move?
Smith: Well, the success of the Hae-
mophilus and the idea that I could become
free of grants. One month later, I went to
Celera.
Gitschier: OK, because then Celera
started up. And Celera’s intent was to
sequence the human genome.
Smith: Yeah, and they picked Craig to
be the president of the company and get
the thing done.
Gitschier: And Craig invited you to
come, too.
Smith: Well, I sort of insisted! He likes
to quote me as saying, ‘‘I don’t think this is
going to work, but I want to go with you.’’
[Laughter]
Gitschier: Really? You didn’t think it
was going to work?
Smith: I knew they could sequence. I
wasn’t sure they could put everything
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said, ‘‘I’m coming with you.’’
Gitschier: OK! So, it’s very interesting
to me, you and he seem to be very
different kinds of people. Yet, you’ve
followed him out here…
Smith: Well—how can I say it? I would
rank him as a genius. Extremely good in
several areas. He’s a superb scientist. He
can see much further ahead than I can. So
he’sreallystartedseveralindependent areas
of research. Like the ocean sampling and
things—huge things that nobody in acade-
mia would even consider doing. We’re able
to do things [at JCVI] that you couldn’t get
any government funding for. It’s too off-
the-wall! They are too big, too costly, and
too indefinite. And he’s really good at that
kind of thing. He’s just an incredibly
fascinating guy. And, he’s willing to pay
me to work.
Gitschier: And you’re working on
amazing stuff. Now, synthetic biology…
where do you view this as going?
Smith: I fully expect that in a few
years—I don’t want to say in how many
years—we’ll be able to design new bacte-
ria. We have to learn a lot before we can
do that. We can already synthesize
genomes. So that—the technical part of
it—is there. The problem now is to know
them well-enough to design organisms,
and then we should be able to make them
do things that we want them to do.
I’m only interested in the science. I
want to learn enough about the essential
genes in cells, because if you’re going to
design an organism, you have to start with
an essential set of genes that make it alive.
Then you can just add stuff onto it. So
then we can have modules that make bio-
fuels or a pharmaceutical product. Just
plug it in. It’s naı ¨ve at this point. But the
future of actually designing bacteria.
Gitschier: And here you are back in
San Diego. It sounds to me that you’ve got
the world’s greatest job!
Smith: Yeah, Craig is the guy that does
everything. I’m just happy that I can
continue to work. I mean I just turned 80
this year.
Gitschier: It’s just fantastic! It’s inspi-
rational, really. I’m wondering what kind
of advice you might have for scientists
starting out today, given that you’ve had
this long and varied career.
Smith: Everybody’s different. It’s hard
to advise anybody. But, do stuff you like to
do. That’s very important for motivation.
You should work on your own ideas, not
other peoples’ ideas, if you can. It’s not
just a job to make money.
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